The Society of Memorial Sloan Kettering Cancer Center (MSK) has forged a long tradition of fueling progress at MSK. Funds raised by dedicated volunteers of The Society have been essential to MSK’s continued innovation and advances in cancer care, research, and education for more than 75 years.
In 2022, The Society returned to hosting its in-person events. The Winter Lunch supported the Adolescent and Young Adult Fertility Preservation Fund at MSK, and in May, The Society celebrated its 15th annual Spring Ball. In attendance was Scott Stuart, Chair of MSK’s Board of Trustees, along with Craig B. Thompson, MD, who was honored for 12 years of leadership ahead of stepping down as MSK President and CEO in September. The Society hosted its first-ever Fall Lunch in October, gifts from which were allocated to the MSK Cancer Health Equity Research and Care Initiative, led by Carol Brown, MD, FACOG, FACS, Senior Vice President, Chief Health Equity Officer, and Nicholls-Biondi Chair for Health Equity.
The Society’s 2022–2023 campaign supported three key efforts in immunotherapy research:
- The investigations of stem cell transplant oncologist Marcel van den Brink, MD, PhD, into gut bacteria’s potential influence on the outcome of immune-based cancer treatments. Dr. van den Brink is Head of the Division of Hematologic Malignancies and holds the Alan N. Houghton Chair.
- The Cell Therapy Correlative Core at MSK, a new hub to support immunotherapy efforts at all stages.
Muffie Potter Aston assumed the role of The Society’s President in May 2022, following three years of distinguished service by Kate Allen. Muffie has been a member of The Society’s Administrative Board since 1999, served as Chair for many of its committees and events, and was Vice Chair of The Society’s Associates Committee. She will continue to build on The Society’s steadfast commitment to strengthening the impact of scientific and clinical leadership at MSK.